DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Treatment of Outpatients With Severe Asthma and Moderate or Severe Major Depressive Disorder

Information source: University of Texas Southwestern Medical Center
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Severe Asthma; Moderate or Severe Major Depressive Disorder

Intervention: Placebo (Drug); Escitalopram (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: University of Texas Southwestern Medical Center

Official(s) and/or principal investigator(s):
E. Sherwood Brown, Ph.D, M.D., Principal Investigator, Affiliation: UT Southwestern Medical Center at Dallas

Summary

The purpose is to determine if: 1) Escitalopram treatment will be associated with less oral corticosteroid use than placebo in outpatients with severe asthma and moderate or severe major depressive disorder (MDD). 2) Escitalopram treatment will be associated with greater improvement in asthma symptoms than placebo in outpatients with severe asthma and moderate or severe MDD. 3) Escitalopram treatment will be associated with greater depressive symptom remission rates than placebo in outpatients with severe asthma and moderate or severe MDD.

Clinical Details

Official title: Escitalopram in the Treatment of Outpatients With Severe Asthma and Moderate or Severe Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Primary outcome:

HAM-D (Hamilton Rating Scale for Depression)

ACQ (Asthma Control Questionnaire)

IDS-SR (Inventory of Depressive Symptomatology - Self-Report)

HAM-D (Hamilton Rating Scale for Depression)

ACQ (Asthma Control Questionnaire)

IDS-SR (Inventory of Depressive Symptomatology - Self-Report)

Detailed description: Primary Aim 1) Determine if escitalopram treatment is associated with less oral corticosteroid use for asthma symptom control than placebo in asthma outpatients with moderate or MDD. Secondary Aims 1. Determine if escitalopram treatment is associated with greater improvement in asthma symptoms than placebo in outpatients with severe asthma and moderate or severe MDD. 2. Determine if escitalopram treatment is associated with greater depressive symptom remission rates than placebo in outpatients with severe asthma and moderate or severe MDD. Background/Significance Asthma is a common, chronic general medical condition characterized by inflammation and variable, but usually reversible, airflow obstruction. Approximately 7. 2% of people in the United States have a history of asthma. Asthma is common with an increasing prevalence and mortality especially in low-income and minority populations. The course of asthma appears to be influenced by mood and emotions. It has been reported that there is a high prevalence of depression or depressive symptoms in both children and adults with asthma. Depression is associated with increased use of asthma-related urgent care services, as well as a variety of unfavorable asthma outcomes. In addition to the possible associations between depression and asthma medication nonadherence and even death, depression appears to be associated with increased use of emergency rooms, hospitals, and unscheduled appointments for asthma. Despite data on the frequency of depression in asthma and its adverse consequences, it is generally not recognized or treated. Our proposed study is different. We observed a modest difference between antidepressant and placebo in a prior trial. However, in a subgroup with more severe asthma (based on frequent corticosteroid use) and more severe depression (based on higher depressive symptoms scores) we saw a much larger effect size. The proposed study will target this subgroup. The sample size is based on the effect size we observed in this subgroup in our previous pilot study. A placebo controlled trial is needed because 1) the primary outcome in our previous trial was not significant. Therefore, it is not clear that antidepressant treatment is effective in depressed asthma patients. 2) We identified a subgroup with greater depressive symptom and asthma severity that based on a post-hoc analysis appeared to show a favorable response to the antidepressant. Thus, we want to confirm these post-hoc findings with a targeted prospective study. In the clinical population we will study, very few patients have ever received assessment or treatment for depression. Therefore, we would not be withholding clearly effective treatment that they would otherwise receive. Standard of care for severe asthma is aggressive asthma treatment. Our study does not require any changes in the patient's asthma treatment. No guidelines are currently available on the treatment of depression in asthma patients. Standard care for depression would be antidepressants.

Eligibility

Minimum age: 18 Years. Maximum age: 70 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Current HAM-D score of ≥ 20

- Patients with severe asthma (defined as asthma requiring three or more course of oral

corticosteroids in the past year).

- No changes in asthma medications, oral corticosteroid use, or treatment for

respiratory tract infections in the past week

- Needs to have taken ≥ 3 courses of oral corticosteroids, for asthma, in the past 12

months.

- Both male and female

- English- or Spanish-speaking

Exclusion Criteria:

- Current substance or alcohol abuse/dependence

- MDD with psychotic features (delusions, hallucinations, disorganized thought

processes)

- Bipolar disorder

- Schizophrenia or schizoaffective disorder

- Substance-induced mood disorder and mood disorder secondary to a general medical

condition

- Mental retardation or other severe cognitive impairment

- Prison or jail inmates

- Pregnant or nursing women or women of childbearing age who will not use The

University of Texas Southwestern Medical Center - Institutional Review Board (UTSW

IRB) approved methods of birth control or abstinence during the study

- Treatment-resistant depressed persons defined as having failed two adequate trials of

antidepressants

- Current antipsychotic or antidepressant therapy or psychotherapy

- Initiation of other psychotropic medications or psychotherapy within past 2 weeks

(e. g., anxiolytics, hypnotics)

Locations and Contacts

The UT Southwestern Medical Center at Dallas, Dallas, Texas 75390, United States
Additional Information

Starting date: March 2008
Last updated: January 2, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017